不含防腐剂的降眼压药物应用前景  

Clinical applications of preservative-free intraocular pressure-lowering drugs:the future prospects

作　　者：黄晶晶(综述)[1] 葛坚(审校)[1] Huang Jingjing;Ge Jian(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science,Guangzhou 510060,China)

机构地区：[1]中山大学中山眼科中心、眼病防治全国重点实验室、广东省眼科视觉科学重点实验室,广州510060

出　　处：《中华实验眼科杂志》2023年第12期1231-1236,共6页Chinese Journal Of Experimental Ophthalmology

基　　金：国家自然科学基金面上项目(82271081)。

摘　　要：长期使用局部降眼压药物,尤其是含防腐剂的降眼压药物可能会引起或加重眼表疾病,进而可能降低患者对药物的耐受性及治疗依从性,也可能增加手术相关风险,最终影响青光眼的治疗效果。因此,青光眼的长期管理有必要综合考虑疗效、安全性、经济学等多方面的因素。为避免防腐剂带来的眼表毒性作用,近年来研发不含防腐剂的(PF)降眼压药物开始广受关注。PF-降眼压药物与其相应的含防腐剂药物相比,具有相似的药动学特性和生物等效性;同时,PF类药物的工艺设计可有助于降低眼表疾病的发生,从而改善患者的体征和症状,有助于提高疗效,具有广阔应用前景。本文将针对PF-降眼压药物的发展历史和临床应用进行综述和讨论,以期加深临床医生对此类药物使用的了解。Long-term use of topical intraocular pressure-lowering medications,particularly those containing preservatives,may cause or worsen ocular surface diseases,which may ultimately reduce patient tolerance and compliance,increase surgical risk,and compromise treatment efficacy.Therefore,long-term management of glaucoma requires the consideration of various factors such as efficacy,safety,and cost-effectiveness.Recently,the use of preservative-free(PF)intraocular pressure-lowering drugs has been gaining considerable attention in research as a means to avoid the toxicity of preservatives on ocular health.These drugs have similar pharmacokinetic properties and bioequivalence to their corresponding preservative-containing drugs.In addition,the manufacturing process of PF medications can reduce the incidence of ocular surface diseases,improve patient symptoms,and increase treatment effectiveness,indicating extensive potential applications.This review focuses on the development and clinical use of PF intraocular pressure-lowering drugs,aiming to deepen clinicians'understanding of their use.

关 键 词：青光眼 眼压 药物治疗 不含防腐剂 研究进展 未来前景 

分 类 号：R775[医药卫生—眼科]